Sinphar strikes Taiwan anticancer deal
This article was originally published in Scrip
The Taiwanese firm Sinphar Pharmaceutical has licensed two early-stage anticancer compounds from Taiwan's National Health Research Institutes. The preclinical stage small molecules act to block vascular and cell proliferation and have shown signs of activity in various cancers including cervical, gastric, colorectal and nasopharyngeal, the partners said. Sinphar, a diversified healthcare group, already markets a generic version of paclitaxel and plans to begin clinical trials with the compounds within the next two years. It recently set up a new domestic biotech subsidiary to discover and develop new drugs and seek further alliances.
You may also be interested in...
Corporate consolidation and specialization were major threads running through the 2010s in Japan. Reimbursement pricing issues continued to dominate the policy sphere while new forms of therapy benefited from positive regulatory reforms.
BeiGene licenses antibody therapeutics for Castleman’s disease and high-risk neuroblastoma.
BeiGene’s license agreement with Leap Therapeutics covers Asia, except for Japan, along with Australia and New Zealand. Apollomics obtains rights in China and beyond to GlycoMimetics’ e-selectin antagonists.